Key takeaway
Pooling 27 studies with 2,242 people with Alzheimer's disease, cognitive scores improved most at about 650 METs-min/week of exercise overall (SMD 0.691) and 660 METs-min/week for aerobic exercise (SMD 0.909). The estimates are model-based and the confidence ranges are wide, so the exact optimum is uncertain.
Study design
Evidence review
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
People with Alzheimer's disease are often told to exercise, but it is unclear how much, and of what kind, helps thinking skills. The authors wanted to map the dose-response curve between weekly exercise volume and cognitive function, and to compare exercise types.
Who and how
Systematic review with a Bayesian model-based network meta-analysis (a method that compares several exercise types and doses across trials at once) of randomized controlled trials in older adults with Alzheimer's disease. The authors searched Web of Science, PubMed, the Cochrane Central Register of Controlled Trials and Embase up to November 2023, assessed quality with the Cochrane Risk of Bias tool (RoB 2), and analyzed data in R with the MBNMA package. Effects are standardized mean differences (SMDs) with 95% credible intervals (CrI). Exercise dose is expressed in METs-min/week, a measure of energy expenditure.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Twenty-seven studies with 2,242 people with Alzheimer's disease showed a nonlinear relationship: more exercise did not simply mean more cognitive benefit.
- 2Cognitive scores improved significantly at exercise doses up to 1000 METs-min/week (SMD 0.535, SD 0.269, 95% CrI 0.023 to 1.092). The lower bound is barely above zero, so the benefit at that dose is uncertain.
- 3The best overall dose was 650 METs-min/week (SMD 0.691, SD 0.169, 95% CrI 0.373 to 1.039), and aerobic exercise looked particularly effective.
- 4For aerobic exercise alone, the best dose was 660 METs-min/week (SMD 0.909, SD 0.219, 95% CrI 0.495 to 1.362).
Limits & uncertainty
- 1The abstract does not report results for other exercise types, so it is unclear how aerobic exercise compares with, for example, resistance training.
- 2The best doses come from a fitted curve across trials with different designs, and the credible intervals are wide, so 650 or 660 METs-min/week is an estimate, not a proven target.
- 3The abstract does not give the risk-of-bias ratings or the severity of dementia in the included trials.
- 4This reading is based on the abstract only.
What to take from it
Moderate regular aerobic activity looks more helpful for thinking skills in Alzheimer's disease than doing none, and more is not necessarily better. Do not treat 660 METs-min/week as a prescription: a person's safe and suitable exercise plan should be set with their care team.
Reading your own data
If you or a relative track activity, a weekly total of active minutes or an energy-expenditure estimate from the same watch or app is the closest match to this dose idea. Watch-based METs-min estimates are rough, so compare weekly trends on one device rather than chasing a precise number.
How to read this evidence
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Objective
Research the dose-response relationship between overall and certain types of exercise and cognitive function in older adults with Alzheimer's disease and dementia.
Design
Systemic and Bayesian Model-Based Network Meta-Analysis.
Methods
In our study, we analyzed data from randomized controlled trials investigating the effects of different exercises on cognitive outcomes in older adults with AD. We searched the Web of Science, PubMed, Cochrane Central Register of Controlled Trials, and Embase up to November 2023. Using the Cochrane Risk of Bias tool (Rob2) for quality assessment and R software with the MBNMA package for data analysis, we determined standard mean differences (SMDs) and 95% confidence intervals (95%CrI) to evaluate exercise's impact on cognitive function in AD.
Results
Twenty-seven studies with 2,242 AD patients revealed a nonlinear relationship between exercise and cognitive improvement in AD patients. We observed significant cognitive enhancements at an effective exercise dose of up to 1000 METs-min/week (SMDs: 0.535, SD: 0.269, 95% CrI: 0.023 to 1.092). The optimal dose was found to be 650 METs-min/week (SMDs: 0.691, SD: 0.169, 95% CrI: 0.373 to 1.039), with AE (Aerobic exercise) being particularly effective. For AE, the optimal cognitive enhancement dose was determined to be 660 METs-min/week (SMDs: 0.909, SD: 0.219, 95% CrI: 0.495 to 1.362).
Conclusion
Nonlinear dose-response relationship between exercise and cognitive improvement in Alzheimer's disease, with the optimal AE dose identified at 660 METs-min/week for enhancing cognitive function in AD.
Sources & attribution
Effective dosage and mode of exercise for enhancing cognitive function in Alzheimer's disease and dementia: a systematic review and Bayesian Model-Based Network Meta-analysis of RCTs.
Yuan Y, Yang Y, Hu X, Zhang L, Xiong Z, Bai Y, Zeng J, Xu F.
BMC geriatrics · 2024-06-01
DOI: 10.1186/s12877-024-05060-8 ↗PubMed · 38824515 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Exercise gave small-to-moderate cognitive gains across 133 reviews of trials
An umbrella review of 133 systematic reviews (2724 trials, 258,279 participants) found that exercise improved general cognition (SMD 0.42, 95% CI 0.37 to 0.47), memory (0.26) and executive function (0.24), with the largest memory gains in children and adolescents and the largest executive function gains in people with ADHD. Most of the reviews (94) were rated critically low in quality and the effects were smaller in the best-rated ones (0.23 for general cognition), and the outcomes were test scores, not dementia.
British Journal of Sports Medicine
More daily steps linked to fewer depressive symptoms across 33 studies of adults
Pooling 33 observational studies of 96,173 adults, higher daily step counts went with fewer depressive symptoms, and in the two prospective cohorts that could be pooled, 7000 or more steps a day went with a lower risk of depression than fewer (RR 0.69, 95% CI 0.62-0.77). Most studies were cross-sectional, so low mood may be reducing steps as much as steps affect mood, and the authors say the prediction intervals call for caution.
JAMA Network Open
Exercise eased depression in 218 trials, but confidence in the evidence is low
In a network meta-analysis of 218 trials with 14,170 people who met criteria for major depression, walking or jogging, yoga, strength training, mixed aerobic exercise and tai chi or qigong each gave moderate reductions in depression compared with active controls (walking or jogging: Hedges' g −0.62, 95% credible interval −0.80 to −0.45). Confidence in the evidence was low for walking or jogging and very low for the other treatments, mainly because only one study met the low-risk-of-bias criteria.
BMJ
Physical activity eased depression and anxiety across 97 reviews of trials
Across 97 systematic reviews that pooled 1039 randomized trials with 128,119 participants, physical activity had medium effects on depression (median effect size −0.43) and anxiety (−0.42) compared with usual care, and higher-intensity activity went with larger gains. Most of those reviews (77) were rated critically low in quality, and the evidence mainly concerns mild-to-moderate symptoms.
British Journal of Sports Medicine

